Mabvi Bioscience

 

It is estimated that over 300 companies offer more than 2.9 million antibodies for science research.  In two large validation studies involving more than 5000 antibodies from many vendors, It was disclosed that 50 to 75% of those antibodies could not recognize what they supposed to. It is conservatively estimated that the use of poor characterized and ill-defined antibodies wastes 700 million dollars annually worldwide, and 350 million dollars in the USA.

Validated antibodies are specific, selective, and reproducible in the context for which they are to be used such as those therapeutic antibodies regulated by FDA. Unfortunately, there are no universally accepted guidelines or standardized methods for determining the validity of the antibodies for science research.

Mabvi Bioscience established a comprehensive validating platform based on the current experts’ opinions and the available cutting edge technologies to fight the irreproducibility crisis in scientific research.

Mabvi Bioscience aims to build better science through our services of antibody validation and producing recombinant antibodies.